


# Use of Antivirals for Prevention and Treatment of Residents During Influenza Outbreaks in Long-Term Care Homes



- It is advised that facilities consult with their medical director for antiviral treatment and prophylaxis decision-making.
- Ill residents starting a treatment dose of antivirals are advised to complete the regimen as prescribed.
- \*It is not necessary to measure creatinine values prior to initiating oseltamivir if the person is not known to have renal problems. **See reverse for information about recommended dosing.**
- \*\*As per page 55, of “Recommendations for the Control of Respiratory Infection Outbreaks in Long-Term Care Homes”, MOHLTC, March 2018.
- **As per AMMI Canada**, treatment should be initiated as rapidly as possible. At-risk groups include individuals 65 years and older and people of any age who are residents of nursing homes or chronic care facilities. Treatment is recommended for those at-risk even if the interval between illness and antiviral administration exceeds 48 hours.
- The MOHLTC reimburses LTCHs and other institutions for the use of oseltamivir for prophylaxis and treatment in residents only during public health-confirmed influenza outbreaks. Supply is limited to a maximum of 6 weeks for prophylaxis and five days for treatment. Please see “Recommendations for the Control of Respiratory Infection Outbreaks in Long-Term Care Homes”, MOHLTC, March 2018.

# Use of Antivirals for Prevention and Treatment of Residents During Influenza Outbreaks in Long-Term Care Homes

TREATMENT	
Status of resident/patient	Dosage for Treatment
No known renal disease or creatinine clearance <b>&gt;60 mL/min</b>	75 mg twice daily for 5 days
Known creatinine clearance of <b>&gt;30- 60 mL/min</b>	75 mg once daily for 5 days OR 30 mg twice daily for 5 days
Known creatinine clearance of <b>10-30 mL/min</b>	30 mg once daily for 5 days
Known to be on hemodialysis or peritoneal dialysis or have a creatinine clearance <b>&lt;10 mL/min</b>	Consult with a specialist regarding appropriate dosing and refer Tamiflu® product monograph.

PROPHYLAXIS	
Status of resident/patient	Dosage for Prevention
No known renal disease or creatinine clearance <b>&gt;60 mL/min</b>	75 mg once daily by mouth until outbreak is declared over
Known creatinine clearance of <b>&gt;30-60 mL/min</b>	30 mg once daily until outbreak is declared over
Known creatinine clearance of <b>10-30 mL/min</b>	30 mg every other day until outbreak is declared over
Known to be on hemodialysis or peritoneal dialysis or have a creatinine clearance <b>&lt;10 mL/min</b>	Consult with a specialist regarding appropriate dosing and refer to Tamiflu® product monograph.

## Side Effects:

- Nausea and vomiting may occur in approximately 2-10% of people. Nausea and vomiting can be minimized if taken with food.
- Other possible side effects include headache and abdominal pain, allergic reactions to the medication and liver toxicity. Please see the Compendium of Pharmaceuticals and Specialties (CPS) or product monograph for more details.

## References:

Aoki, F. Y., Allen, U.D., Mubareka, S., Papenburg, J., Stiver, H. G., Evens, G.A. (2019). *Use of antiviral drugs for seasonal influenza: Foundation document for practitioners-Update 2019*. Available online at: <https://jammi.utpjournals.press/doi/pdf/10.3138/jammi.2019.02.08>

Aoki, F. Y., Allen, U.D., Evans, G.A., *Laverdière, M.* Stiver, H.G. (2015). *Guidance on the use of antiviral drugs for influenza in acute care facilities in Canada, 2014-2015*. Available online at: [www.ammi.ca/guidelines](http://www.ammi.ca/guidelines)

Aoki, F. Y., Allen, U. D., Stiver, H. G., & Evans, G. A. (2013). The use of antiviral drugs for influenza: A foundation document for practitioners, Autumn 2013. Available online at: [www.ammi.ca/guidelines](http://www.ammi.ca/guidelines)

Hoffman-La Roche Canada. (January 26, 2015). Product Monograph <sup>PR</sup>Tamiflu®. Available online at: [www.rochecanada.com/en/products/pharmaceuticals/consumer\\_information/tamiflu.html](http://www.rochecanada.com/en/products/pharmaceuticals/consumer_information/tamiflu.html)

Ministry of Health and Long Term Care. (March 2018). Recommendations for the Control of Respiratory Infection Outbreaks in Long-Term Care Homes. Available online at: [www.health.gov.on.ca/en/pro/programs/publichealth/oph\\_standards/docs/reference/RESP\\_Infectn\\_ctrl\\_guide\\_LTC\\_2018\\_en.pdf](http://www.health.gov.on.ca/en/pro/programs/publichealth/oph_standards/docs/reference/RESP_Infectn_ctrl_guide_LTC_2018_en.pdf)